期刊文献+

急性髓细胞白血病患者外周血淋巴细胞亚群的特征及临床意义 被引量:7

下载PDF
导出
摘要 目的通过检测急性髓细胞白血病患者外周血各淋巴细胞亚群的分布,探讨该类患者免疫功能状况。方法通过流式细胞术检测健康对照组(n=20)、急性髓细胞白血病初发患者(n=31)及完全缓解期患者(n=31)外周血中CD4+T细胞、CD8+T细胞、TCRγδ+T细胞、CD4+CD25+调节性T细胞(Treg)、CD16+CD56+NK细胞比例;通过细胞杀伤实验分析NK细胞和γδT细胞的杀伤活性以及与Treg的关系。结果与对照组相比,初发白血病患者和完全缓解患者外周血中CD4+T细胞、CD8+T细胞比例无明显差异,但CD4+CD25+Treg比例明显增高,TCRγδ+T细胞和CD16+CD56+NK细胞比例明显下降。初发病患者NK细胞和γδT细胞具有杀伤活性,但Treg能明显抑制其杀伤活性。结论急性髓细胞白血病患者外周血γδT和NK细胞虽具有杀伤功能,但比例明显下降,Treg对其杀伤功能具有抑制作用。
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2015年第2期244-247,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 江苏省自然科学基金(BK20131248) 镇江市社会发展支撑计划(SH2013031)
  • 相关文献

参考文献19

  • 1Yanada M, Tsuzuki M, Fujita H, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia[J] Blood, 2013, 121 ( 16 ) : 3095 - 3102.
  • 2Zhang Y, Zlmng Z, Li J, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia [J]. Cancer, 2013, 119 ( 1 ) : 115 - 125.
  • 3Iland H J, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute pmmyelocytie leukemia ( APML4 ) [J ]. Blood, 2012, 120 ( 8 ) : 1570 - 1580.
  • 4Anguille S, Willemen Y, Lion E, et al. Dendritic cell vaccination in acute myeloid leukemia [J ]. Cytotherapy. 2012, 14 ( 6 ) : 647 - 656.
  • 5张国庆,焦顺昌,温新宇,赵宏,林星石,吴亮亮.大肠癌患者与正常健康人淋巴细胞表型差异分析[J].细胞与分子免疫学杂志,2012,28(7):735-737. 被引量:5
  • 6王晗,李妍,杨宁,苑雯文,谢娜,王大刚,郭桐生,毛远丽.丙型肝炎患者外周血淋巴细胞亚群变化特点[J].细胞与分子免疫学杂志,2014,30(10):1058-1061. 被引量:4
  • 7Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer [ J ]. Nat Rev Immunol, 2007, 7(5) : 329 -339.
  • 8Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells[J]. Nat Immunol, 2008, 9(5) : 503 -510.
  • 9Chaput N, Darrasse-Jeze G, Bergot AS, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites[J]. J Immunol, 2007, 179(8) : 4969 -4978.
  • 10Liu Z, Kim JH, Falo LD Jr, et al. Tumor regulatory T cells potently abrogate antitumor immunity [ J]. J Immunol, 2009, 182 ( 10 ) : 6160 - 6167.

二级参考文献42

共引文献13

同被引文献72

  • 1Chitadze G, Bhat J, Lettau M, et al. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications[J]. Scand J Immunol, 2013, 78(2) : 120 - 129.
  • 2Huergo-Zapico L, Acebes-Huerta A, IApez-Soto A, et al. Molecular bases for the regulation of NKG2D ligands in cancer [ J/OL]. Front Immunol, 2014, 5: 106.
  • 3Nanbakhsh A, Pochon C, Mallavialle A, et al. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility toNK-mediated lysis [ J ]. Blood, 2014, 123(23) : 3585 -3595.
  • 4Mao C, Qin W, Chen D, et al. A monoclonal antibody against human gL16-binding protein 3 [ J]. Hybridoma ( Larchmt), 2012, 31(3) : 203 -208.
  • 5Yoon SR, Kim TD, Choi I. Understanding of molecular mechanisms in natural killer cell therapy [ J/OL]. Exp Mol Med, 2015, 47 : e141.
  • 6Eguizabal C, Zenarruzabeitia O, Mange J, et al. Natural killer cells for cancer i mmunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective [ J/OL]. Front Immunol, 2014, 5 : 439.
  • 7Fu D, Geschwind JF, Karthikeyan S, et al. Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B [J/OL]. Oncoimmunology, 2015, 4(3) : e991228.
  • 8Eagle RA, Jafferji I, Barrow AD. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells[ J]. Curt Immunol Rev, 2009, 5(1) : 22 -34.
  • 9Ullrich E, Koch J, Cerwenka A, et al. New prospects on the NKG2D/NKG2DL system for oncology [ J/OL ]. Oncoimmunology, 2013, 2(10) : e26097.
  • 10Lopez-Soto A, Zapico LH, Acebes-Huerta A, et al. Regulation of NKG2D signaling during the epithelial-tomesenchymal transition [J/OL]. Oncoimmunology, 2013, 2(9): e25820.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部